Dermata Therapeutics, Inc.

Biotechnology • Healthcare • San Diego, CA, United States • DRMAW (NCM)

Dermata Therapeutics, Inc., a late-stage medical dermatology company, focuses on identifying, developing, and commercializing pharmaceutical product candidates for the treatment of medical skin diseases and aesthetic applications. Its lead product candidate is XYNGARI, which is in Phase 3 clinical studies for the treatment of moderate-to-severe acne, as well as completed Phase 1b proof of concept (POC) trial for mild-to-moderate psoriasis. The company is also developing DMT410 that has completed Phase 1b POC trials for the treatment of axillary hyperhidrosis and aesthetic skin conditions. It has a clinical trial collaboration agreement with Revance Therapeutics, Inc. to conduct a multi-center clinical trial to evaluate the topical application of XYNGARI with DAXXIFY, Revance's botulinum toxin type A. Dermata Therapeutics, Inc. was incorporated in 2014 and is headquartered in San Diego, California.

858 800 2543 3525 Del Mar Heights Rd., San Diego, CA 92130, United States

Stock Performance (90 Days)

Data through Dec 26, 2025

Price updates on page refresh. Intraday quotes available during market hours (9:30 AM - 4:00 PM EST).

Layoff History

No layoff events recorded for this company.

Recent News

Dermata Therapeutics Announces Closing of up to $12.4 Million Private Placement Priced At-The-Market Under Nasdaq Rules - Yahoo Finance

Yahoo Finance • Dec 29

Why Did Dermata Therapeutics Stock Surge 22% Pre-Market Today? - Stocktwits

Stocktwits • Dec 24

Dermata lines up as much as $12.4M to help launch OTC acne kit - Stock Titan

Stock Titan • Dec 24

Dermata Therapeutics stock soars after securing $4.1 million private placement - Investing.com

Investing.com • Dec 24

Dermata Therapeutics: Is Change on the Horizon? - StocksToTrade

StocksToTrade • Dec 30

Other Biotechnology Companies

Vertex Pharmaceuticals Inc. / MA

$118.68B market cap

Regeneron Pharmaceuticals, Inc.

$82.72B market cap

Alnylam Pharmaceuticals, Inc.

Frequently Asked Questions

Has Dermata Therapeutics, Inc. had layoffs?

No layoff events have been recorded for Dermata Therapeutics, Inc. in our database. This could mean the company has not conducted significant layoffs, or any layoffs have not been publicly reported.

How many employees does Dermata Therapeutics, Inc. have?

Dermata Therapeutics, Inc. has approximately 8 employees.

What industry is Dermata Therapeutics, Inc. in?

Dermata Therapeutics, Inc. operates in the Biotechnology industry, within the Healthcare sector.

Is Dermata Therapeutics, Inc. a publicly traded company?

Yes, Dermata Therapeutics, Inc. is publicly traded under the ticker symbol DRMAW on the NCM.

Where is Dermata Therapeutics, Inc. headquartered?

Dermata Therapeutics, Inc. is headquartered in San Diego, CA, United States at 3525 Del Mar Heights Rd., San Diego, CA 92130, United States.

Disclaimer

Data aggregated from public sources including WARN notices, SEC filings, press releases, and market data. While we strive for accuracy, information is provided "as-is" for informational purposes only. Always verify critical information with official company sources.

This information does not constitute investment, financial, legal, or career advice. See our Terms of Service, Privacy Policy, and About page for more information.

Found an error? Report it here.